LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article: Interview mit Julie Flygare

    Flygare, Julie

    Der Wecker

    2019  Volume 66, Issue -, Page(s) 36

    Language German
    Document type Article
    ZDB-ID 1089979-0
    Database Current Contents Medicine

    More links

    Kategorien

  2. Article ; Online: Narcolepsy and COVID-19: sleeping on an opportunity?

    Fernandez, Fabian-Xosé / Flygare, Julie / Grandner, Michael A

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

    2020  Volume 16, Issue 8, Page(s) 1415

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/physiopathology ; Humans ; Narcolepsy/complications ; Narcolepsy/immunology ; Narcolepsy/physiopathology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/physiopathology ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-03-04
    Publishing country United States
    Document type Letter
    ZDB-ID 2397213-0
    ISSN 1550-9397 ; 1550-9389
    ISSN (online) 1550-9397
    ISSN 1550-9389
    DOI 10.5664/jcsm.8520
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.

    Morse, Anne Marie / Krahn, Lois / Flygare, Julie / Kushida, Clete / Thorpy, Michael J / Athavale, Amod / Gudeman, Jennifer

    Advances in therapy

    2023  Volume 40, Issue 7, Page(s) 3199–3216

    Abstract: Introduction: Immediate-release sodium oxybate (SXB) has been Food and Drug Administration (FDA)-approved to treat narcolepsy since 2002; in 2020, a mixed-salt oxybates formulation was also approved. Both are taken at bedtime with a second dose taken 2 ... ...

    Abstract Introduction: Immediate-release sodium oxybate (SXB) has been Food and Drug Administration (FDA)-approved to treat narcolepsy since 2002; in 2020, a mixed-salt oxybates formulation was also approved. Both are taken at bedtime with a second dose taken 2.5-4 h later. A third oxybate option, an investigational extended-release SXB, may soon be available. This study was undertaken to understand clinicians' preferences between these 3 different oxybate treatments.
    Methods: Clinicians in active clinical practice for 3-35 years and experience treating patients with narcolepsy were recruited. A 30-min web-based survey quantified narcolepsy disease-state attitudes, treatment perceptions, and satisfaction with oxybates on 9-point scales. A discrete choice experiment (DCE) of 12 choice sets, with 2 hypothetical treatment profiles in each, was used to capture clinician preferences about overall oxybate therapy preference, impact on patient quality of life (QoL), and patient anxiety/stress. Attributes associated with current therapies and those expected to be available in the near future were included in the design.
    Results: The clinicians surveyed (n = 100) indicated that narcolepsy has a negative impact on patient QoL (mean rating, 7.7) and rated impact on QoL and treatment efficacy as the most important aspects of a narcolepsy treatment (mean rating, 7.3-7.7). Clinicians with experience prescribing oxybates had moderately high satisfaction with SXB and mixed-salt oxybates efficacy (mean ratings, 6.5-6.9) and safety (mean ratings, 6.1-6.7) and lower satisfaction with nightly dosing frequency (mean rating, 5.9 and 6.3, respectively). In the DCE, dosing frequency was the most important attribute driving overall product choice, patient QoL, and reducing patient anxiety/stress (relative attribute importance, 46.1, 41.7, and 44.0, respectively), with once nightly preferred over twice nightly.
    Conclusion: Clinicians indicated a significantly higher preference for the once-at-bedtime dosing schedule versus twice nightly in selecting oxybate therapies overall and when aiming to improve patient QoL or reduce patient anxiety.
    MeSH term(s) Humans ; Sodium Oxybate/adverse effects ; Quality of Life ; Narcolepsy/drug therapy ; Narcolepsy/complications ; Treatment Outcome ; Surveys and Questionnaires
    Chemical Substances Sodium Oxybate (7G33012534)
    Language English
    Publishing date 2023-05-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-023-02532-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Living with Narcolepsy: Current Management Strategies, Future Prospects, and Overlooked Real-Life Concerns.

    Barker, Emily C / Flygare, Julie / Paruthi, Shalini / Sharkey, Katherine M

    Nature and science of sleep

    2020  Volume 12, Page(s) 453–466

    Abstract: Narcolepsy is a neurological disorder of the sleep-wake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep disturbances, and REM-sleep-related phenomena (sleep paralysis, hallucinations) that intrude into wakefulness. ... ...

    Abstract Narcolepsy is a neurological disorder of the sleep-wake cycle characterized by excessive daytime sleepiness (EDS), cataplexy, nighttime sleep disturbances, and REM-sleep-related phenomena (sleep paralysis, hallucinations) that intrude into wakefulness. Dysfunction of the hypocretin/orexin system has been implicated as the underlying cause of narcolepsy with cataplexy. In most people with narcolepsy, symptom onset occurs between the ages of 10 and 35 years, but because the disorder is underrecognized and testing is complex, delays in diagnosis and treatment are common. Narcolepsy is treated with a combination of lifestyle modifications and medications that promote wakefulness and suppress cataplexy. Treatments are often effective in improving daytime functioning for individuals with narcolepsy, but side effects and/or lack of efficacy can result in suboptimal management of symptoms and, in many cases, significant residual impairment. Additionally, the psychosocial ramifications of narcolepsy are often neglected. Recently two new pharmacologic treatment options, solriamfetol and pitolisant, have been approved for adults, and the indication for sodium oxybate in narcolepsy has been expanded to include children. In recent years, there has been an uptick in patient-centered research, and promising new diagnostic and therapeutic options are in development. This paper summarizes current and prospective pharmacological therapies for treating both EDS and cataplexy, discusses concerns specific to children and reproductive-age women with narcolepsy, and reviews the negative impact of health-related stigma and efforts to address narcolepsy stigma.
    Language English
    Publishing date 2020-07-16
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2587468-8
    ISSN 1179-1608
    ISSN 1179-1608
    DOI 10.2147/NSS.S162762
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Introducing People-Centered Language to SLEEP.

    Buysse, Daniel J / Parthasarathy, Sairam / Flygare, Julie

    Sleep

    2017  Volume 40, Issue 4

    Language English
    Publishing date 2017-04-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 424441-2
    ISSN 1550-9109 ; 0161-8105
    ISSN (online) 1550-9109
    ISSN 0161-8105
    DOI 10.1093/sleep/zsx038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Narcolepsy: let the patient's voice awaken us!

    Flygare, Julie / Parthasarathy, Sairam

    The American journal of medicine

    2014  Volume 128, Issue 1, Page(s) 10–13

    MeSH term(s) Female ; Humans ; Narcolepsy/diagnosis ; Narcolepsy/psychology ; Narcolepsy/therapy ; Primary Health Care
    Language English
    Publishing date 2014-06-12
    Publishing country United States
    Document type Case Reports ; Editorial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2014.05.037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy.

    Maski, Kiran / Steinhart, Erin / Williams, David / Scammell, Thomas / Flygare, Julie / McCleary, Kimberly / Gow, Monica

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

    2017  Volume 13, Issue 3, Page(s) 419–425

    Abstract: Study objectives: Describe common symptoms, comorbidities, functional limitations, and treatment responsiveness among patients with narcolepsy. Investigate the effect of pediatric onset of narcolepsy symptoms on time to diagnosis of narcolepsy and ... ...

    Abstract Study objectives: Describe common symptoms, comorbidities, functional limitations, and treatment responsiveness among patients with narcolepsy. Investigate the effect of pediatric onset of narcolepsy symptoms on time to diagnosis of narcolepsy and presence of comorbid depression.
    Methods: Cross-sectional survey of 1,699 people in the United States with self-reported diagnosis of narcolepsy. We utilized mixed-methods data analyses to report study findings.
    Results: Most participants reported receiving a diagnosis of narcolepsy more than 1 y after symptom onset. We found that the strongest predictor of this delayed diagnosis was pediatric onset of symptoms (odds ratio = 2.4, p < 0.0005). Depression was the most common comorbidity but we detected no association with pediatric onset of narcolepsy symptoms. Overall, participants reported that fatigue and cognitive difficulties were their most burdensome symptoms in addition to sleepiness and cataplexy. The majority of participants reported residual daytime fatigue and/or sleepiness despite treatment. Most participants reported they could not perform at work or school as well as they would like because of narcolepsy symptoms.
    Conclusions: This study provides unique insight into the narcolepsy disease experience. The study quantifies the problem of diagnostic delay for narcolepsy patients in the United States and highlights that symptoms are more likely to be missed if they develop before 18 y of age. These results suggest that narcolepsy awareness efforts should be aimed at parents, pediatric health care providers, school professionals, and children/adolescents themselves. Disease burden is high because of problems with fatigue, cognition, and persistence of residual symptoms despite treatment.
    Language English
    Publishing date 2017-03-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2397213-0
    ISSN 1550-9397 ; 1550-9389
    ISSN (online) 1550-9397
    ISSN 1550-9389
    DOI 10.5664/jcsm.6494
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Transition-State Metal Aryl Bond Stability Determines Regioselectivity in Palladium Acetate Mediated C–H Bond Activation of Heteroarenes

    Petit, Alban / Flygare Josh / Miller Alex T / Winkel Gerrit / Ess Daniel H

    Organic letters. 2012 July 20, v. 14, no. 14

    2012  

    Abstract: Density functional calculations reveal that the stability of developing metal aryl bonds in Pd(II)-acetate C–H activation transition states determines regioselectivity in arene and heteroarene compounds. This kinetic–thermodynamic connection explains ...

    Abstract Density functional calculations reveal that the stability of developing metal aryl bonds in Pd(II)-acetate C–H activation transition states determines regioselectivity in arene and heteroarene compounds. This kinetic–thermodynamic connection explains the general preference for activation of the strongest C–H bond and provides the possibility for regioselectivity prediction.
    Keywords acetates ; aromatic hydrocarbons ; carbon-hydrogen bond activation ; chemical bonding ; chemical reactions ; chemical structure ; palladium ; prediction ; regioselectivity
    Language English
    Dates of publication 2012-0720
    Size p. 3680-3683.
    Publishing place American Chemical Society
    Document type Article
    ISSN 1523-7052
    DOI 10.1021%2Fol301521n
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  9. Article: Diffusion studies of bovine serum albumin by quasielastic light scattering

    Raj, T / Flygare, W.H

    July 30, 1974, 13 (16)

    1974  

    Keywords zoology ; livestock ; animal science
    Language English
    Dates of publication 1974-0730
    Size p. 3336-3340.
    Document type Article
    Database NAL-Catalogue (AGRICOLA)

    Kategorien

To top